<DOC>
	<DOCNO>NCT02104830</DOCNO>
	<brief_summary>The purpose study compare safety efficacy single dose empegfilgrastim daily dose filgrastim prevention neutropenia patient receive AT ( docetaxel 75 mg/m2 + doxorubicin 50 mg/m2 ) .</brief_summary>
	<brief_title>Study Efficacy Safety Empegfilgrastim Neutropenia Prophylaxis Breast Cancer Patients</brief_title>
	<detailed_description>BCD-017-3 double-blind randomized phase III clinical study compare incidence CTCAE grade 3/4 neutropenia single administration recombinant human pegylated filgrastim empegfilgrastim ( Extimia® ) dose 6 7.5 mg versus daily administration filgrastim dose 5 μg/kg/day neutropenia prophylaxis breast cancer patient receive myelosuppressive chemotherapy . The study also include follow determination pharmacokinetic parameter repeat administration study drug .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Signed informed consent form ; Histologically verify diagnosis stage IIb/III/IV breast cancer ; Age 1870 year inclusive ; Life expectancy least 6 month inclusion study ; If patient receive chemotherapy breast cancer , finish 30 day begin study ; ECOG Performance Status 0 2 , increase within 2 week randomization ; ANC level 1500/μL begin study Platelet count 100 000/μL beginning study Hemoglobin level 90 g/l Creatinine level &lt; 1.5 mg/dl Total bilirubin level &lt; 1.5 × upper limit normal ( ULN ) ALT and/or AST level &lt; 2.5×ULN ( 5×ULN patient liver metastasis ) ; Alkaline phosphatase &lt; 5×ULN ; Left ventricular ejection fraction &gt; 50 % ; If patient receive adjuvant and/or neoadjuvant therapy , cumulative dose anthracyclines exceed 250 mg/m2 doxorubicin 540 mg/m2 epirubicin , study plan 6 cycle chemotherapy ; If patient receive adjuvant and/or neoadjuvant therapy , cumulative dose anthracyclines exceed 350 mg/m2 doxorubicin 660 mg/m2 epirubicin , study plan 4 cycle chemotherapy ; Ability participant follow protocol requirement , accord Investigator 's opinion ; Patients childbearing potential must implement reliable contraceptive measure study treatment , start 4 week prior randomization 6 month last administration study drug ; Patients able follow Protocol procedure ( accord Investigator 's assessment . Patient receive two chemotherapy regimen metastatic breast cancer ; Documented hypersensitivity filgrastim , pegfilgrastim , docetaxel , doxorubicin , dexamethasone and/or excipients , PEGylated drug , recombinant protein . Pregnancy breastfeeding ; Systemic antibiotic therapy within 72 h prior empegfilgrastim/filgrastim administration ; Concomitant radiotherapy ( except selective radiotherapy bone metastasis ) ; Surgery , radiotherapy ( except selective radiotherapy bone metastasis ) , administration experimental drug within 30 day prior randomization ; History bone marrow/stem cell transplantation ; Conditions limit patient 's ability follow protocol ; CTCAE grade 34 neuropathy ; HIV , HCV , HBV , T.Pallidum infection ( ) ; Acute active chronic infection ; Severe concurrent disease ( example , severe arterial hypertension , severe heart failure , ) ; Severe depression , schizophrenia , mental disorder ; Obstacles intravenous administration study drug ; Simultaneous participation clinical trial , previous participation clinical trial within 30 day enter trial , previous participation trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>empegfilgrastim</keyword>
	<keyword>pegylated filgrastim</keyword>
	<keyword>neutropenia</keyword>
	<keyword>febrile neutropenia</keyword>
	<keyword>chemotherapy-associated neutropenia</keyword>
	<keyword>breast cancer</keyword>
	<keyword>docetaxel</keyword>
	<keyword>doxorubicin</keyword>
</DOC>